ACS pharmacology & translational science

Possible Heart Risks of Small LSD Doses in Mice

Updated

Abstract

Essence

Low-dose LSD did not produce detectable ventricular or valvular remodeling in this mouse microdosing model.

Evidence

This preclinical mouse experiment used echocardiography after chronic serotonin, d-fenfluramine, vehicle, or two subhallucinogenic LSD doses, with added 5-HT2B receptor assays.

Caveat

The safety boundary is limited to mice, the tested doses, and 4- to 8-week cardiac endpoints, not long-term human microdosing.

Simplified

Full Text

Full text is available at the source.

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free